Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.
Fiche publication
Date publication
juin 2016
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Girerd N, Medeiros PB, Santos M, Carvalho HC, Bettencourt P, Kénizou D, Butler J, Zannad F, Rossignol P
Lien Pubmed
Résumé
Loop diuretic resistance characterized by inefficient sodium excretion complicates many patients with acutely decompensated heart failure (ADHF). Mineralocorticoid receptor antagonists (MRAs) in natriuretic doses may improve spot urine sodium excretion and outcomes.
Mots clés
Aged, Aged, 80 and over, Biomarkers, urine, Chi-Square Distribution, Female, France, Heart Failure, drug therapy, Hospitalization, Humans, Kaplan-Meier Estimate, Linear Models, Male, Middle Aged, Mineralocorticoid Receptor Antagonists, adverse effects, Multivariate Analysis, Natriuresis, drug effects, Potassium, urine, Predictive Value of Tests, Proportional Hazards Models, Prospective Studies, Risk Factors, Sodium, urine, Sodium Potassium Chloride Symporter Inhibitors, therapeutic use, Spironolactone, adverse effects, Time Factors, Treatment Outcome, Urinalysis
Référence
Clin Res Cardiol. 2016 Jun;105(6):489-507